Compass Therapeutics to Participate in Upcoming May Investor Events
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May.
Details are as follows:
The Citizens Life Sciences Conference
Location: New York, NY
Date: Thursday, May 8, 2025
Time: 1:30 PM ET
Webcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Location: New York, NY
Date: Tuesday, May 20, 2025
Time: 11:30AM ET
Webcast Link: https://journey.ct.events/view/29729b86-5109-46dc-a93b-1cf3560aa9a1
Virtual/Replay availability: Presentations will be archived for 90 days on Compass' Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
37 minutes ago
- Business Wire
LFMD Investors Have Opportunity to Join LifeMD, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of LifeMD, Inc. ('LifeMD' or 'the Company') (NASDAQ: LFMD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. LifeMD announced its Q2 2025 financial results on August 5, 2025. The Company revealed higher customer acquisition costs had added pressure on the business, especially related to its RexMD telehealth platform. Analysts from KeyBanc Capital Markets indicated that the Company 'took its eye off the ball' in the quarter, leading to its share price to drop more than 44.8% on the next day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Insider
an hour ago
- Business Insider
BABA vs. AMZN: Which ‘Mega-Cap' Cloud Stock Has More Upside, According to Wall Street Analysts?
Mega-cap stocks are those with a market capitalization of $200 billion or more. Most of these stocks are associated with large, well-established companies with strong track records. Due to their sheer size, mega-cap stocks are often considered safe bets during uncertain macroeconomic times. Using TipRanks' Stock Comparison Tool, we will compare Alibaba (BABA) and Amazon (AMZN) to see which mega-cap stock has more upside ahead, according to Wall Street analysts. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alibaba (NYSE:BABA) Stock Alibaba is China's largest e-commerce and cloud-services company, running platforms such as Taobao, Tmall, and AliCloud. The stock has surged more than 45% this year, fueled by AI-driven cloud demand and strong momentum in instant delivery services. Recently, Alibaba has ramped up efforts in its core e-commerce business. Taobao expanded its one-hour delivery service to 50 cities, hitting over 40 million daily orders during peak campaigns. The company launched a ¥10 billion ($1.4 billion) subsidy plan to compete with and Meituan in the fast-delivery space. In addition, Alibaba merged its food delivery unit, and travel services, Fliggy, into Taobao and Tmall to strengthen its retail ecosystem. Looking ahead, the company is set to report its Q1 FY26 earnings soon. Wall Street expects Alibaba to report earnings of $2.16 per share for Q1, down 6% from the year-ago quarter. The decline could be due to the company's heavy investment in logistics and delivery. Meanwhile, analysts project Q1 revenues at $35.49 billion, up 6% year-over-year. Is Alibaba Stock a Good Buy Right Now? Mizuho's Top analyst, Wei Fang, maintained an Outperform rating but trimmed the price target from $160 to $149, citing concerns about rising competition and lower near-term profitability. According to him, rising competition in China's local commerce sector, especially in food delivery and instant retail, is beginning to hurt the company's bottom line. Overall, Wall Street has a Strong Buy consensus rating on Alibaba stock based on 13 Buys and one Hold. The average Alibaba price target of $150.09 implies about 23.78% upside potential from current levels. Amazon Stock (NASDAQ:AMZN) Amazon, the global e-commerce and cloud leader, delivered better-than-expected Q2 2025 earnings. The stock has surged about 5% so far this year, driven by strength in its cloud unit, Amazon Web Services (AWS). The company is making continuous efforts to boost spending on AI infrastructure to drive long-term growth. At the same time, Amazon is doubling down on its grocery business. It recently expanded its 'Amazon Fresh' store rollout in the U.S. and is testing faster same-day grocery delivery to strengthen its retail footprint. This move is designed to increase customer loyalty and complement its Prime ecosystem. What Is the Price Target for Amazon Stock? In response to Amazon's latest grocery push, Morgan Stanley analyst Brian Nowak highlighted that expanding the grocery selection on should help the company cut delivery costs while lowering the minimum basket size. He noted that this move is part of Amazon's broader effort to capture a larger share of the $1.5 trillion offline grocery market. Based on 44 Buys and one Hold recommendation, Amazon stock earns a Strong Buy consensus rating on TipRanks. The average AMZN stock price target of $265.22 implies 14.8% upside potential from current levels. Conclusion Wall Street remains bullish on both Alibaba and Amazon stocks. However, analysts see greater upside potential in Alibaba. The Chinese giant is betting big on instant commerce and subsidies to defend market share. Meanwhile, Amazon is expanding its grocery and AI bets to drive long-term growth. While its upside may be smaller than Alibaba's, Amazon's stable growth and strong cash flow continue to earn Wall Street's confidence.
Yahoo
an hour ago
- Yahoo
CoreWeave Crashes 46% After Lockup--Is This the AI Bargain of the Year or a Falling Knife?
CoreWeave's (NASDAQ:CRWV) post-IPO honeymoon may be ending. After skyrocketing more than fourfold by mid-June, the stock has come back to earthfalling 46% from its June 20 peak. The trigger? Over 80% of Class A shares just became eligible for sale as the IPO lockup expired. That timing came two days after CoreWeave's second earnings report, which revealed a wider-than-expected loss despite a raised 2025 revenue forecast. The stock has already dropped 33% this week alone, with analysts flagging the potential for more downside as early investors head for the exit. Warning! GuruFocus has detected 5 Warning Signs with CRWV. The selloff could create both risk and opportunity. CoreWeave now trades at a roughly $49 billion market cap, down from a June high of $88 billion. Its free floatpreviously under 15%could expand significantly as insiders begin selling. That's likely what spooked the market, according to Roundhill CEO Dave Mazza, who called it a challenging, even confusing setup. Citi's Tyler Radke echoed that sentiment, warning of short-term pressure but suggesting that a more liquid float might attract new buyers. Meanwhile, Nvidia (NASDAQ:NVDA)CoreWeave's key AI chip supplierisn't going anywhere. It actually increased its stake in Q2 to 6.5%, now worth about $2.4 billion. The long-term bull case hasn't vanished. CoreWeave is still spending aggressivelyup to $23 billion this yearto meet rising AI demand, and counts Microsoft as its largest customer. But execution risk is climbing, especially with its all-stock acquisition of Core Scientific looming. Hedge funds like Magnetar and Coatue may opt to ease out slowly to avoid triggering further panic. D.A. Davidson's Gil Luria has a $36 price target, implying over 60% downside from recent levels. Whether this marks a healthy reset or the beginning of a deeper unwind depends on who shows up to buyif anyone does. This article first appeared on GuruFocus. Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
